New Peer-Reviewed Research Shows Comprehensive Care Model Drives Superior GLP-1 Outcomes

Two studies in Obesity Pillars find Ivim Health patients on GLP-1 therapy achieved over 20% average weight loss with integrated lifestyle support.

Mar. 12, 2026 at 6:15pm

Got story updates? Submit your updates here. ›

Two peer-reviewed studies published in Obesity Pillars demonstrate that patients receiving GLP-1 therapy within Ivim Health's comprehensive care protocol achieved higher average weight loss than reported in certain pharmaceutical trials. The difference was attributed to intensive medical oversight, personalized treatment, and integrated lifestyle support.

Why it matters

The research contributes to growing evidence that care delivery infrastructure significantly impacts GLP-1 therapy outcomes, with implications for how healthcare systems, providers, and payers approach obesity treatment. The studies offer a roadmap for comprehensive GLP-1 care delivery through virtual care models.

The details

In a real-world cohort receiving tirzepatide-based therapy, patients achieved 22.74% average weight loss at 52 weeks and 26.54% at 72 weeks. Over 99% achieved clinically meaningful weight loss, and nearly two-thirds lost more than 20% of their body weight. A parallel study evaluating semaglutide-based therapy showed nearly identical results: 21.8% weight loss at 68 weeks, with 99.2% reaching clinical significance.

  • The tirzepatide cohort study was published in Obesity Pillars in 2026.
  • The semaglutide cohort study was published in Obesity Pillars in 2025.

The players

Ivim Health

A national virtual healthcare provider specializing in individualized weight care and the treatment of cardiometabolic conditions including obesity.

Dr. Jessica Duncan

Chief Medical Officer and board-certified obesity medicine physician at Ivim Health, and lead author of the studies.

Dr. Taylor Kantor

Chief Innovation Officer and co-founder of Ivim Health.

Dr. Daniel J Rosen

Founder and lead physician at Weight Zen in New York.

Got photos? Submit your photos here. ›

What they’re saying

“What these studies demonstrate is what's achievable when you build comprehensive care around GLP-1 therapy. When patients have consistent access to their medical team, when treatment adapts to their individual response, when they receive integrated support — outcomes were observed to improve in these cohorts. This is the standard of care patients deserve.”

— Dr. Jessica Duncan, Chief Medical Officer and board-certified obesity medicine physician (Ivim Health)

“This data further solidifies the notion that a patient care model emphasizing regular clinical access to providers, including nutritional optimization and behavioral modification, with a focus on emotional support and regular exercise, can lead to superior weight loss outcomes compared to protocols dedicated to medication administration alone.”

— Dr. Daniel J Rosen, Founder and lead physician (Weight Zen)

“Obesity care is specialty care and deserves dedicated infrastructure. Through my background in cardiac surgery, I saw what comprehensive protocols achieved in surgical patients. What these cohorts demonstrate is that modern telehealth can deliver that level of specialty care at scale.”

— Dr. Taylor Kantor, Chief Innovation Officer and co-founder (Ivim Health)

What’s next

The relatively small number of patients on FDA-approved medications in these studies limits the strength of direct formulation comparisons. Additional controlled trials would be needed to firmly establish causation between the comprehensive care model and the superior outcomes observed.

The takeaway

This research suggests that a care delivery model emphasizing regular clinical access, personalized treatment, and integrated lifestyle support can lead to significantly better weight loss outcomes for patients on GLP-1 therapies compared to medication-only approaches. Maximizing the value of GLP-1 therapy may require investment in comprehensive care infrastructure, not just medication access.